Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer,
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …
[HTML][HTML] Mechanisms of cancer metastasis
M Castaneda, P den Hollander, NA Kuburich… - Seminars in cancer …, 2022 - Elsevier
Metastatic cancer is almost always terminal, and more than 90% of cancer deaths result from
metastatic disease. Combating cancer metastasis and post-therapeutic recurrence …
metastatic disease. Combating cancer metastasis and post-therapeutic recurrence …
[HTML][HTML] Randomized trial of cytoreductive surgery for relapsed ovarian cancer
Background Treatment for patients with recurrent ovarian cancer has been mainly based on
systemic therapy. The role of secondary cytoreductive surgery is unclear. Methods We …
systemic therapy. The role of secondary cytoreductive surgery is unclear. Methods We …
[HTML][HTML] Tumor angiogenesis: causes, consequences, challenges and opportunities
R Lugano, M Ramachandran, A Dimberg - Cellular and Molecular Life …, 2020 - Springer
Tumor vascularization occurs through several distinct biological processes, which not only
vary between tumor type and anatomic location, but also occur simultaneously within the …
vary between tumor type and anatomic location, but also occur simultaneously within the …
Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG …
KN Moore, M Bookman, J Sehouli, A Miller… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To evaluate the addition of the humanized monoclonal antiprogrammed death
ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and …
ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and …
[HTML][HTML] Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
Background Olaparib has shown significant clinical benefit as maintenance therapy in
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …
Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology
DK Armstrong, RD Alvarez, JN Bakkum-Gamez… - Journal of the National …, 2021 - jnccn.org
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States and is the country's fifth most common cause of cancer mortality in women. A …
United States and is the country's fifth most common cause of cancer mortality in women. A …
Epithelial ovarian cancer: evolution of management in the era of precision medicine
S Lheureux, M Braunstein… - CA: a cancer journal for …, 2019 - Wiley Online Library
Ovarian cancer is the second most common cause of gynecologic cancer death in women
around the world. The outcomes are complicated, because the disease is often diagnosed …
around the world. The outcomes are complicated, because the disease is often diagnosed …
[HTML][HTML] ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours …
The development of guidelines recommendations is one of the core activities of the
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …
Epithelial ovarian cancer
Epithelial ovarian cancer generally presents at an advanced stage and is the most common
cause of gynaecological cancer death. Treatment requires expert multidisciplinary care …
cause of gynaecological cancer death. Treatment requires expert multidisciplinary care …